Richard Norton peptide death leads Victorian coroner to seek TGA review

A Victorian coroner has found that the Richard Norton peptide death in March 2025 was triggered by injections of two unapproved compounds, CJC1295 and Ipamorelin, which a doctor had prescribed and a Queensland pharmacy had made up. Coroner David Ryan delivered his findings on Wednesday 28 October and asked the Therapeutic Goods Administration to review the benefits and risks of such peptides and to consider further limits on their use. The 75 year old actor, stuntman and martial arts instructor is believed to be the first confirmed death in Australia from unapproved peptide use.

What the Victorian coroner found

Norton worked for decades in film and television, and his circle included well known Hollywood actors. According to the findings as reported by ABC News, he collapsed and went into cardiac arrest soon after injecting CJC1295 and Ipamorelin, and he died at the Alfred Hospital in Melbourne on 30 March 2025. Mr Ryan found that the death followed complications from his use of the two products. He also said Norton "had been taking amounts of the medication in excess of the dose prescribed by his medical practitioner". That detail shapes how the Richard Norton peptide death should be read. ABC's account does not mention any finding about contamination or a faulty batch, so the case as reported centres on an experimental treatment used above the prescribed amount.

Norton told his doctor, Jerzy Muchnicki, that another practitioner had prescribed peptides to him before, for fatigue, slow physical recovery, shoulder pain and loss of lean muscle. He had asthma, osteoarthritis and two past shoulder reconstructions. The findings say Dr Muchnicki reviewed his history, explained that the treatment was experimental, discussed its risks and noted that the regulator had approved no alternative treatment. Norton signed a written consent form, and blood tests were ordered to check his baseline health. In the days before he died, he said he felt good and that his symptoms were improving. He also told a nurse at the clinic that he had been injecting twice the prescribed amount. The nurse advised him to go back to the prescribed amount from the following week, and he collapsed hours after that talk.

Why unapproved peptides reach Australian patients

This was not a case of a product bought from an anonymous website. The two peptides reached Norton through a prescription from a registered doctor, and a licensed compounding pharmacy in Queensland prepared them for him. The coroner's report noted the TGA's advice that various pathways let medical practitioners obtain unapproved peptides for their patients. Yet in its statement after the findings, the regulator said it has never evaluated such products for safety, quality or effectiveness. That gap sits at the centre of the coroner's request. A prescription and a licensed pharmacy can confirm that the supply chain is lawful, but they cannot show that the compound itself works or is safe. No regulator has reviewed that evidence for these two peptides in Australia.

A prescription and a licensed pharmacy can confirm that the supply chain is lawful, but they cannot show that the compound itself works or is safe.

The death adds to wider concern in Australia about injectable peptides. In recent weeks ABC News has reported a surge in peptide related hospital visits in New South Wales, and harm reduction charities overwhelmed by peptide users asking for free syringes. In September the TGA disclosed that an unapproved weight loss product labelled as retatrutide had left a patient with a torn oesophagus. These reports involve different products and routes of supply, and none of them shows how common serious harm is. They do show the regulator handling several kinds of peptide risk at once, from compounded prescriptions like Norton's to products of uncertain content sold outside the medical system. Regulators abroad face a related problem, as the seizure of counterfeit weight loss pens at a Birmingham industrial unit recently showed.

Medical Board of Australia caution for the prescriber

According to the coroner's report, concerns about how Dr Muchnicki treated Norton were formally raised with Ahpra, the national agency that regulates health practitioners. The Medical Board of Australia then investigated and sought a report from clinical professor Alistair Vickery. His view on the drugs was blunt: "There is insufficient evidence that CJC1295/Ipamorelin is safe, effective or beneficial for human use." On the doctor's conduct he was more measured. Taking into account Dr Muchnicki's training and experience, the written consent and Norton's earlier peptide use without adverse effects, he concluded that "the clinical care provided by Dr Muchnicki was at a standard reasonably expected". The split matters. The expert found little evidence for the treatment itself, yet he judged the clinical care acceptable within the rules that allow such prescribing.

Professor Vickery was critical of the paperwork. He described the doctor's notes as "sparse, inadequate and perfunctory" and said his performance on that point fell below the expected standard. The board's investigation recorded that Dr Muchnicki accepted the criticism and took responsibility, said sorry for misjudgements and for gaps in his records, and voiced regret over what happened to Norton and his family. He has engaged an educator for personal training in clinical record keeping and management. In July 2026 the board found his practice "is or may be unsatisfactory" but decided that regulatory action was not warranted. He received a caution and had conditions imposed. ABC News said it had contacted Dr Muchnicki for comment, and the table below sets out the sequence.

What the TGA could do next

Under the coroner's recommendation, the national regulator should weigh what compounds like CJC1295 and Ipamorelin may offer patients against the harm they can cause, and then "consider whether further restrictions ought to be imposed on their use". The regulator responded with a statement. It said it "continues to warn consumers about the risks of unapproved peptides which have not been assessed by the TGA for safety, quality or effectiveness", and that it had also passed those warnings to health practitioners. "We are continuing to assess the risks associated with these products and considering whether further regulatory or other measures may be appropriate," the statement said, according to the ABC report. The TGA did not say which measures it is weighing, which products they would cover or when it might decide.

Several questions stay open after the Richard Norton peptide death. Neither the coroner nor the regulator, as reported, gave a figure for how many Australians are prescribed CJC1295 and Ipamorelin, or how many compounding pharmacies prepare them. It is also unclear whether any new limits would target the access pathways doctors use, the compounding step, or the peptides themselves. Product quality is a separate concern in other markets, where an FDA import alert recently barred two Chinese GLP 1 ingredient plants after inspections. For Australian patients, the practical point today is simple: these two peptides remain unassessed by the national regulator. We will track the TGA response and related decisions on our Asia-Pacific desk as they come.

Conclusion

The Richard Norton peptide death is believed to be the first confirmed Australian fatality from unapproved peptides, and the products came through a prescription and a licensed compounding pharmacy. As reported, the coroner named no specific restriction. He asked the Therapeutic Goods Administration to weigh the evidence and decide whether tighter limits are needed. The TGA says it is considering further measures but has set no date. This report is for information only and is not medical advice.